comparemela.com
Home
Live Updates
Galapagos NV: Galapagos presented encouraging initial safety
Galapagos NV: Galapagos presented encouraging initial safety
Galapagos NV: Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL
All 7 out of 7 eligible patients with relapsed/refractory Chronic Lymphocytic Leukemia, with or without Richter's transformation, responded to treatment (Objective Response Rate of 100%)GLPG5201 showed
Related Keywords
Mechelen ,
Region Flamande ,
Belgium ,
Japan ,
Julio Delgado ,
Mercedes Montoro ,
Leticia Alserawan ,
Valentin Ortiz Maldonado ,
Christian Jacques ,
Schwierige Zeiten ,
Paul Stoffels ,
Van Gijsel ,
Sandra Cauwenberghs ,
Nuria Martinez Cibrian ,
Marieke Vermeersch ,
Margotj Pont ,
Daniel Estban ,
Sergi Betriu ,
Elisa Chenailler ,
Exchange Commission ,
European Society For Blood ,
Twitter ,
European Hematology Association ,
Chronic Lymphocytic Leukemia ,
Objective Response Rate ,
European Society ,
Marrow Transplantation ,
Small Lymphocytic Lymphoma ,
Clinical Results ,
Maike Spoon ,
Bayesian Optimal Interval ,
Lymphocytic Leukemia ,
Small Lymphocytic Leukemia ,
B Cell Non Hodgkin ,
Cancer Journal ,
Galapagos ,
Resented ,
Ncouraging ,
Nitial ,
Safety ,
Efficacy ,
Data ,
023 ,
Bmt ,
Joint ,
Mare ,
Manufactured ,
Candidate ,
Lpg5201 ,
Rcll ,